Izrael - hebrejčina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 50 mg - voriconazole - voriconazole - treatment of: invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei) serious fungal infections caused by scedosporium spp. and fusarium spp. vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.

Izrael - hebrejčina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 200 mg - voriconazole - voriconazole - treatment of: invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei),serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.

Izrael - hebrejčina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - אבקה להכנת תמיסה לאינפוזיה - voriconazole 200 mg/vial - voriconazole - voriconazole - treatment of :- invasive aspergillosis fluconazole-resistant serious invasive candida infections (including c. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.

Izrael - hebrejčina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - אבקה להכנת תרחיף - voriconazole 40 mg/ml - voriconazole - voriconazole - treatment of : invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei) , serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.

Izrael - hebrejčina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 200 mg - voriconazole

Izrael - hebrejčina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 200 mg - voriconazole

Izrael - hebrejčina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - טבליות מצופות פילם - voriconazole 50 mg - voriconazole

Izrael - hebrejčina - Ministry of Health

padagis israel agencies ltd, israel - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab

Izrael - hebrejčina - Ministry of Health

kamada ltd, israel - human normal immunoglobulin - תמיסה לאינפוזיה - human normal immunoglobulin 50 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - 1.replacement therapy in: primary immunodeficiency syndromes such as: - congenital agammaglobulinemia and hypogammaglobulinemia - common variable immunodeficiency - severe combined immunodeficiency - wiskott aldrich syndromemyeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinemia and recurrent infectionschildren with congenital aids and recurrent infections2. immunomodulation: - idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count- guillain barr? syndrome- kawasaki disease3. allogeneic bone marrow transplantation

Izrael - hebrejčina - Ministry of Health

kamada ltd, israel - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 100 mg/ml - immunoglobulins, normal human, for intravascular adm.